NASDAQ · REPLHealthcareBiotechnology

Replimune Group financials

$13.00+3.50%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY26
Mar 31
FY25
Mar 31
FY24
Mar 31
FY23
Mar 31
FY22
Mar 31
FY21
Mar 31
FY20
Mar 31
FY19
Mar 31
Revenue$0.00$0.00$0.00$0.00————
Gross profit$0.00$0.00$0.00$0.00————
Gross margin————————
Operating income-$319.9M-$261.6M-$234.8M-$177.1M-$115.1M-$77.1M-$56.2M-$28.4M
Net income-$313.9M-$247.3M-$215.8M-$174.3M-$118.0M-$80.9M-$52.6M-$30.8M
Net margin————————
Diluted EPS$-3.38$-3.07$-3.24$-2.99$-2.26$-1.75$-1.54$-1.33
EBITDA-$316.6M-$258.1M-$232.1M-$174.6M-$113.0M-$75.4M-$55.7M-$28.3M
Operating cash flow-$280.3M-$192.3M-$185.5M-$128.1M-$82.2M-$61.4M-$60.6M-$25.4M
Free cash flow-$284.6M-$198.9M-$191.1M-$130.3M-$84.5M-$63.8M-$67.1M-$28.0M
Diluted shares92.8M80.6M66.6M58.2M52.2M46.2M34.3M23.2M

Balance sheet

Period endMar 31Mar 31Mar 31Mar 31Mar 31Mar 31
Cash & equivalents$209.0M$111.1M$74.5M$146.6M$105.9M$182.5M
Short-term investments$59.9M$372.7M$346.2M$436.8M$289.7M$293.8M
Total debt$108.1M$71.9M$70.9M$55.3M$27.0M$27.2M
Total assets$332.4M$551.3M$487.7M$646.6M$461.2M$543.1M
Total liabilities$166.2M$135.5M$113.2M$91.3M$50.0M$44.4M
Shareholders' equity$166.2M$415.8M$374.5M$555.3M$411.2M$498.7M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology